Quarterly report pursuant to Section 13 or 15(d)

Collaboration and Research Arrangements - Schedule of Change in Accounts Receivable, Contract Assets and Liabilities (Details)

v3.21.1
Collaboration and Research Arrangements - Schedule of Change in Accounts Receivable, Contract Assets and Liabilities (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
USD ($)
Disaggregation Of Revenue [Line Items]  
Accounts receivable and contract assets, Balance at Beginning of Period $ 2,331
Accounts receivable and contract assets, Additions 5,019
Accounts receivable and contract assets, Deductions (4,728)
Accounts receivable and contract assets, Balance at End of Period 2,622
Contract liabilities, Balance at Beginning of Period 22,086
Contract liabilities, Additions 71
Contract liabilities, Deduction (2,205)
Contract liabilities, Balance at End of Period 19,952
Incyte  
Disaggregation Of Revenue [Line Items]  
Contract liabilities, Balance at Beginning of Period 5,365
Contract liabilities, Deduction (809)
Contract liabilities, Balance at End of Period 4,556
Global Blood Therapeutics  
Disaggregation Of Revenue [Line Items]  
Contract liabilities, Balance at Beginning of Period 16,721
Contract liabilities, Additions 71
Contract liabilities, Deduction (1,396)
Contract liabilities, Balance at End of Period 15,396
Billed receivables from collaboration partners  
Disaggregation Of Revenue [Line Items]  
Accounts receivable, Balance at Beginning of Period 7
Accounts receivable, Additions 2,397
Accounts receivable, Deduction (2,404)
Unbilled receivables from collaboration partners  
Disaggregation Of Revenue [Line Items]  
Contract assets, Balance at Beginning of Period 2,324
Contract assets, Additions 2,622
Contract assets, Deduction (2,324)
Contract assets, Balance at End of Period $ 2,622